Moderna : Des attentes 2024 revues à la baisse. Un marché du RSV compétitif
>Un T2 2024 supérieur aux attentes en topline… - Moderna a publié hier ses résultats du T2 2024 qui a conduit à ajuster à la baisse ses attentes 2024. Les résultats du T2 sont en eux-mêmes bons avec des revenus supérieurs aux attentes alors que le management avait pré-orienté autour de 300 M$ lors du S1. Ce n’est donc pas une surprise que les ventes de Spikevax ont fortement diminué pour atteindre 184 M$ sur ce T2. Sur le plan opérationnel, l’EBIT ressort à -1.4 Md$ (...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.